NASDAQ:BYSI BeyondSpring (BYSI) Stock Price, News & Analysis $2.00 -0.04 (-1.96%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.00 0.00 (0.00%) As of 08/8/2025 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About BeyondSpring Stock (NASDAQ:BYSI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BeyondSpring alerts:Sign Up Key Stats Today's Range$1.92▼$2.1150-Day Range$1.69▼$3.4052-Week Range$0.98▼$3.44Volume23,009 shsAverage Volume25,304 shsMarket Capitalization$80.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey. Read More Receive BYSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BeyondSpring and its competitors with MarketBeat's FREE daily newsletter. Email Address BYSI Stock News HeadlinesBeyondSpring Inc. Reports Promising Results of Plinabulin Combination Therapy in Patients Refractory to Immune Checkpoint Inhibitors - NasdaqJuly 8, 2025 | nasdaq.comBeyondSpring Inc. Reports Promising Results of Plinabulin Combination Therapy in Patients Refractory to Immune Checkpoint InhibitorsJuly 7, 2025 | quiverquant.comQYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything… | Crypto 101 Media (Ad)BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor FailureJuly 7, 2025 | globenewswire.comBeyondSpring reports promising phase 2 NSCLC study resultsJune 5, 2025 | uk.investing.comBeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual MeetingJune 3, 2025 | globenewswire.comBeyondSpring Announces Poster Presentation at 2025 ASCO Annual MeetingMay 29, 2025 | finance.yahoo.comCan BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth?May 15, 2025 | finance.yahoo.comSee More Headlines BYSI Stock Analysis - Frequently Asked Questions How have BYSI shares performed this year? BeyondSpring's stock was trading at $1.63 at the beginning of the year. Since then, BYSI stock has increased by 22.7% and is now trading at $2.00. How were BeyondSpring's earnings last quarter? BeyondSpring Inc. (NASDAQ:BYSI) announced its quarterly earnings results on Monday, May, 12th. The company reported ($0.06) earnings per share (EPS) for the quarter. When did BeyondSpring IPO? BeyondSpring (BYSI) raised $4 million in an initial public offering (IPO) on Thursday, March 9th 2017. The company issued 200,000 shares at a price of $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) served as the underwriter for the IPO. Who are BeyondSpring's major shareholders? Top institutional shareholders of BeyondSpring include Geode Capital Management LLC (0.64%). How do I buy shares of BeyondSpring? Shares of BYSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BeyondSpring own? Based on aggregate information from My MarketBeat watchlists, some other companies that BeyondSpring investors own include Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Alibaba Group (BABA), NIO (NIO), Bristol Myers Squibb (BMY) and NVIDIA (NVDA). Company Calendar Last Earnings5/12/2025Today8/08/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BYSI CIK1677940 Webwww.beyondspringpharma.com Phone(646) 305-6387Fax1-646-882-4228Employees80Year Founded2010Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.49 Quick Ratio2.49 Sales & Book Value Annual Sales$1.75 million Price / Sales46.08 Cash FlowN/A Price / Cash FlowN/A Book Value($0.37) per share Price / Book-5.41Miscellaneous Outstanding Shares40,320,000Free Float28,499,000Market Cap$80.64 million OptionableOptionable Beta0.26 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:BYSI) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeyondSpring Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BeyondSpring With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.